Search Results

You are looking at 61 - 70 of 294 items for :

  • "Neoadjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

CLO20-050: Effect of Tumor Grade on Neoadjuvant Treatment Outcome in Esophageal Cancer

Jordan McDonald, Rutika Mehta, Sarah Hoffe, and Jose Pimiento

stage 1 disease were much less likely to receive neoadjuvant chemotherapy than those with stage 3 disease. Tumor grade was not significantly associated with treatment response (P=0.551), negative margin resection (P=0.252), disease recurrence (P=0

Full access

CLO20-060: Factors Associated with the Uptake of Adjuvant Pertuzumab in Patients with Stage I-III HER2-positive Breast Cancer: The University of Colorado Cancer Center Experience

Ericson Stoen, Jodi Kagihara, Peter Kabos, Christine Fisher, and Jennifer R. Diamond

.01). Hormone receptor status and prior pathologic complete response to neoadjuvant chemotherapy (if given) did not correlate with P administration. Conclusions: In our study, the use of adjuvant P was common in high-risk patients including premenopausal women

Full access

QIM22-207: Physical Therapy Assessment for Management of Breast Cancer Related Lymphedema After Axillary Lymph Node Dissection

Kevin Zhang, Ladan Navari, Amy Li, Sandy Lee, Yevgeniya Gokun, Min-Jeong Cho, Roman Skoracki, and Ko Un Park

.2% PLVB vs 31.9% without PLVB) but completed fewer post-op PT appointments (p<0.0001) (Table1). Patients who received neoadjuvant chemotherapy or adjuvant radiation were more likely to have a pre-op PT appointment, while those who received either adjuvant

Full access

CLO22-059: Chemotherapy Timing and Outcomes in Early Breast Cancer

Kristen Kelley, Audrey York, Benjamin Haaland, Xuechen Wang, Shiven Patel, Adriana Coletta, and Christos Vaklavas

chemotherapy may be superior. The objective of this study is to assess the relationship between dose timing and outcomes in breast cancer patients. Methods : 153 patients who had neoadjuvant chemotherapy in 2014-2020 were included. Chemotherapy administration

Full access

CLO21-024: Serial Circulating Tumor DNA Analysis for Treatment Monitoring in an Inflammatory Triple-Negative Breast Cancer Patient

Urmeel Patel, Nicole Hook, Meenakshi Malhotra, Perry Olshan, Paul R. Billings, Alexey Aleshin, and Angel Rodriguez

patient underwent neoadjuvant chemotherapy with dose dense AC (ddAC) followed by paclitaxel. Following one month, the patient underwent radical mastectomy, followed by adjuvant treatment and periodic radiological imaging, along with circulating tumor DNA

Full access

CLO23-032: Treatment of HER2+ Breast Cancer: A Retrospective of Disease Prognosis With Loss of HER2 Amplification on Residual Disease After Neoadjuvant Treatment in a Community Hospital Setting

Dariusz Uczkowski, Arunabh Sekhri, Shilpi Gupta, Leah Gendler, Krzysztof Misiukiewicz, Miles Levin, and Bonni Guerin

Background: Neoadjuvant chemotherapy (NAC) with Anti-Human Epidermal Growth Factor Receptor 2 (Anti-HER2) agents has increased rates of pathologic complete response (pCR) in stage II-III HER2+ breast cancer. Several retrospective studies have

Full access

CLO22-060: > 3 Courses of Neo-Adjuvant Chemotherapy (NACT) May Affect Outcomes of Advanced Ovarian Serous Adenocarcinoma Patients

Yunyun Liu, KKL Chan, and Hui Zhou

Purpose : Neoadjuvant chemotherapy (NACT) can reduce tumor burden, lower difficulty of surgery in advanced ovarian cancer. However, the option of NACT cycle is still highly controversial. This paper intends to explore whether the number of NACT

Full access

CLO22-051: Influence of Environmental Temperature on Pathological Complete Response and Overall Survival in Breast Cancer: A National Cancer Database Population-Based Study

Ashish Gupta, Kristopher Attwood, Kush Gupta, Asha Gandhi, Stephen Edge, Kazuaki Takabe, and Shipra Gandhi

CD8 + T Cells and higher immunosuppressive cells] than mice housed at 30°C. The incidence of cancer has been shown to be higher in colder climates. A pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) for early-stage breast

Full access

CLO20-055: Optimal Timing of Radical Surgery From Diagnosis in Muscle Invasive Bladder Cancer (MIBC)

Saurabh Parasramka, Quan Chen, Bin Huang, Peng Wang, and Zin Myint

after diagnosis adversely effects survival outcomes. Neoadjuvant chemotherapy (NAC) has become the standard of care for appropriate patients, which delays definitive surgery. Optimal timing of surgery from the time of diagnosis is uncertain when done

Full access

Quality Indicators in the Management of Bladder Cancer

Jeffrey S. Montgomery, David C. Miller, and Alon Z. Weizer

-based neoadjuvant chemotherapy for patients with T2–T4 localized bladder cancer followed by radical cystectomy to optimize disease outcomes. 15 Perioperative Intravesical Chemotherapy Studies dating back to the early 1990s evaluated the use of immediate